Status:
UNKNOWN
Purify Antigen-specific B Cells From Patients With Rheumatoid Arthritis
Lead Sponsor:
University Hospital, Montpellier
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18-65 years
Brief Summary
Rheumatoid arthritis (RA) is an autoimmune disease characterized by the presence of autoantibodies directed against citrullinated proteins, called ACPAs. These antibodies are very specific to RA, and ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- \- Antibodies anti-CCP + (ACPA +) \> 250 IU/mL
- Exclusion criteria:
- Current or past Rituximab (Mabthera) treatment past (\< 9 months)
- Abatacept treatment
Exclusion
Key Trial Info
Start Date :
December 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2024
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT05203952
Start Date
December 1 2021
End Date
January 1 2024
Last Update
February 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UH Montpellier
Montpellier, France, 34295